[Solved] Effect of psychedelics such as psilocybin on GLP-1

There is currently no convincing evidence that psilocybin from magic mushrooms or truffles directly increases GLP-1 levels or acts as a GLP-1 agonist like semaglutide. However, there are clear similarities between the two systems, as they influence the same areas of the brain involved in appetite, reward and motivation.

The fact that many people lose their appetite almost entirely during a psychedelic experience does not, therefore, automatically mean that GLP-1 levels are increased. The most likely explanation lies in the powerful effect that psychedelics have on the serotonin system.

Psilocybin is converted in the body into psilocin, which primarily activates the serotonergic 5-HT2A receptor and also affects other serotonin receptors. Serotonin plays an important role in feelings of satisfaction, satiety and well-being. When these receptors are more strongly activated, many people temporarily experience a reduced need for food and other forms of immediate reward.

It seems that not only does physical hunger diminish, but above all, so does the mental focus on food. During a psychedelic experience, the focus often shifts to emotions, thoughts, insights and sensory experiences. As a result, hunger takes a back seat in one’s consciousness. Some researchers believe that psychedelics reduce the so-called "motivational salience" of food. The body still needs energy, but food temporarily feels less important or less appealing.

This mechanism bears striking similarities to GLP-1 medication. GLP-1 agonists not only reduce appetite, but also diminish the appeal of food. Many users describe food as being less of an obsessive presence in their thoughts. The difference is that GLP-1 achieves this via hormones, vagal signalling and hypothalamic circuits, whilst psychedelics primarily act via serotonergic receptors and changes in brain networks.

Interestingly, both systems appear to converge in brain regions such as the hypothalamus, the ventral tegmental area (VTA) and the nucleus accumbens. These are key centres for motivation, reward and craving. Consequently, GLP-1 medication and psychedelics can produce subjectively similar effects on appetite, despite their underlying pharmacology being very different.

There are also a number of early animal studies in which psilocybin is combined with GLP-1 agonists. These studies found evidence of beneficial effects on weight and metabolism. However, in these studies, psilocybin did not significantly alter GLP-1 levels itself. Changes were, however, observed in other gut hormones such as PYY, GIP and leptin. The current hypothesis is therefore that serotonergic and GLP-1-related systems operate in parallel and may potentially reinforce each other, without psilocybin itself being a GLP-1 agonist.

LSD and MDMA

For LSD (analogues) The same applies to a large extent. LSD also has a strong effect on serotonergic receptors and often reduces one’s focus on food. For MDMA The situation is slightly different. MDMA increases serotonin, dopamine and noradrenaline simultaneously and also activates the sympathetic nervous system. The reduced appetite experienced whilst on MDMA therefore partly resembles the effects seen with stimulants: increased alertness, elevated body temperature, reduced focus on food and, in some cases, nausea.

A comparison with dreams

There’s another interesting one a comparison with sleep and dreams. Whilst sleeping, the body still needs energy, but eating is temporarily not a priority. Something similar happens during a psychedelic experience: the brain is intensely engaged in internal processing and pays less attention to normal needs such as eating. The difference is that with psychedelics, you are actually highly conscious, whereas during sleep you are largely unconscious. The common element is that food temporarily becomes less relevant to consciousness.

The effect of GLP-1 on psychedelics

Conversely, there is also interest in whether GLP-1 medication affects the effects of psychedelics. There are anecdotal reports from users of semaglutide and similar drugs who experience a slower or weaker onset of action from oral psilocybin. One possible explanation is that GLP-1 agonists significantly slow down gastric emptying, causing psilocybin to be absorbed later or in a less predictable manner. There is currently insufficient scientific evidence to support this, and no large-scale controlled studies have yet been conducted in humans.

The best conclusion, based on current knowledge and scientific articles, is that truffles, magic mushrooms, LSD and MDMA are unlikely to have any direct effect on GLP-1, or only a minimal one. The reduced appetite experienced during a psychedelic experience appears to stem primarily from serotonergic activation, feelings of contentment, altered attention, reduced food reward and a temporary shift in what the brain considers important. This feels similar to the effects of GLP-1 medication, as both systems ultimately influence the same appetite and reward networks, but via different receptor systems and biological pathways.

In short: there is no hard evidence (as yet) that psilocybin, LSD or MDMA act directly on the GLP-1 receptor in the same way as a GLP-1 agonist, but there are conceptual links via serotonin, gut hormones and reward circuits, as well as very early animal data in which psilocybin is combined with GLP-1-like interventions. The loss of appetite you experience after a trip stems primarily from 5-HT2A/5-HT2C mediation in the hypothalamus, insula, amygdala and VTA/NAc (plus sympathetic activation and gastrointestinal effects), and only indirectly via the same networks in which GLP-1 also exerts its effects.

1. What do we actually know from research?

1. Psilocybin: mouse models of obesity show that neither a single high dose nor microdosing has any clear lasting effect on weight or food intake; psilocybin does, however, normalise other gut hormones (GIP, PYY, leptin), but does not significantly alter GLP-1 levels.

2. A study involving chronic psilocybin administration in rats observed metabolic effects and discussed how GLP-1 and DPP-4 inhibition can synergistically reduce body weight and appetite, but psilocybin itself does not act as a GLP-1 agonist in this context.[pmc.ncbi.nlm.nih]

3. Recent reviews on the “serotonin/GLP‑1 axis” emphasise that serotonin and GLP‑1 interact with one another in the gut and in the brain, but that, according to current data, psilocybin acts primarily via serotonergic receptors and GLP-1 acts primarily via the incretin and NTS/hypothalamus pathways.

4. For LSD and MDMA: there are (as far as has been published to date) no direct studies which show a change in GLP-1 levels or GLP-1 receptor function; the appetite-suppressing effect is attributed to serotonin, dopamine and sympathetic activation, rather than to GLP-1.

2. Why does your appetite disappear after taking psilocybin/LSD/MDMA?

Psilocybin / classic psychedelics

1. Psilocybin and psilocin are potent agonists at 5-HT2A and, to some extent, 5-HT2C receptors, which are also present in hypothalamic appetite circuits and in the insula/reward system.

2. 5-HT2A activation shifts salience and interoception: attention is directed towards internal experience and sensory input, whilst homeostatic signals such as hunger exert less of a “pull” on attention; this closely resembles how GLP‑1 agonists attenuate food reward and cue responsiveness, but via different receptor families.

3. Acute sympathetic activation (slightly increased heart rate, tension in the body) and nausea during the ‘come-up’ further suppress the urge to eat, independently of GLP-1.

LSD

1. LSD has an even broader serotonergic effect (5‑HT1A/2A/2C, dopaminergic components); like psilocybin, it often reduces appetite by altered salience, sensory overload, and sympathetic activation.

2. There is no evidence that LSD specifically increases or decreases GLP-1 or incretins; the overlap with GLP-1 lies mainly in the network effect: reduced food reward, reduced focus on bodily cravings.

MDMA

1. MDMA causes a massive increase in synaptic serotonin, noradrenaline and dopamine, with a strong sympathetic component (fight-or-flight physiology)

2. The combination of increased core arousal, jaw tension, hyperthermia and possible nausea is in itself sufficient to suppress hunger; this is a classic effect of stimulants and need not involve a GLP-1 component.

3. Does GLP-1 influence psychedelic experiences (and vice versa)?

Psilocybin + GLP-1 agonists (semaglutide, etc.)

1. Early animal studies combine psilocybin with a GLP-1 agonist (semaglutide) and find synergistic effects on weight and glucose regulation in obese mice; psilocybin normalises, amongst other things, GIP and PYY, whilst GLP-1 agonism acts via the classical satiety pathway.

2. These studies refer to a possible “serotonin/GLP-1 axis”: serotonergic modulation via psilocybin, combined with incretin modulation via GLP-1, may together have a greater effect on metabolism and eating behaviour than either would have on its own, but this is still at the preclinical stage.

3. A recent review explicitly states that psilocybin no effect on GLP-1 levels showed this, but in relation to other gut hormones, suggesting that GLP-1 and serotonin-psilocybin pathways run in parallel and may influence one another functionally, without psilocybin itself being “a GLP-1 agent”.

GLP-1 medication as a “trip-killer”?

1. Clinical and harm-reduction sources report anecdotal evidence that GLP-1 agonists (Ozempic, Wegovy, etc.) may affect the effects of psilocybin-containing magic mushrooms in some people smooth out or slow down, possibly caused by:

   1. Significantly delayed gastric emptying → oral psilocybin is absorbed more slowly or erratically, leading to a delayed or flattened onset.

   2. Altered gut-hormone mix and vagal signalling, which modulate the cerebral response.

2. This is largely anecdotal and based on hypotheses; there are as yet no large-scale controlled human studies, only case series and mouse studies.

4. Overlap in circuits: why it feels so “the same” in terms of appetite

Both GLP-1 and psychedelics affect hypothalamus + mesolimbic reward system:

1. GLP-1 agonists: strong evidence that they act in the brain (NTS → hypothalamus, VTA, nucleus accumbens) inhibiting homeostatic hunger and dampening the dopamine response to palatable food, making food feel less rewarding and less “compelling”.

2. Psychedelics: via 5-HT2A-driven changes in the insula, default-mode network and mesolimbic dopamine, the subjective salience stimuli; food temporarily loses its emotional priority, just like other habits or compulsions.

3. Intuitively, they seem similar: less appetite, fewer food cravings, a greater sense of detachment from food. However:

   1. GLP-1 achieves this via incretin-NTS-hypothalamus pathways and relatively stable signals lasting weeks or months.

   2. Psychedelics achieve this through acute serotonergic receptor activation and short-term shifts in network dynamics.

5. Practical takeaways for your question

1. Truffles/magic mushrooms As far as is currently known, they have no direct effect on GLP-1 levels or GLP-1 receptors; the appetite-suppressing effect is due to serotonin/dopamine and autonomic effects.

2. GLP-1 agonists and psychedelics do share target areas (hypothalamus, VTA, NAc), where they reduce the “hunger” for food via incretin and serotonergic/dopaminergic mechanisms, respectively.

3. The combination of psilocybin and GLP-1 in humans has hardly been studied and is not routinely recommended; data from mice suggest metabolic synergy, but safety and neuropsychiatric interactions remain unclear.

4. The fact that your appetite disappears completely after taking psilocybin/LSD/MDMA is therefore entirely consistent with the well-known monoamine and stress response effects, and does not necessarily have to be directly linked to GLP-1; it feels similar to a GLP-1 agonist because both systems “dampen” the same appetite and reward networks.